Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 5 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors at 4 institutions in 1 country.
Pedro Cruz-NovaDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-I.P.N.), Gustavo A. Madero, Mexico City 07360, Mexico.
Blanca Ocampo-GarcíaDepartamento de Materiales Radiactivos, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0002-5831-8412
Dayan Andrea Carrión-EstradaDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-I.P.N.), Gustavo A. Madero, Mexico City 07360, Mexico.ORCID 0000-0001-9168-0918
Paola Briseño-DiazDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-I.P.N.), Gustavo A. Madero, Mexico City 07360, Mexico.
Guillermina Ferro-FloresDepartamento de Materiales Radiactivos, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0003-0296-7605
Nallely Jiménez-MancillaDepartamento de Materiales Radiactivos, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.ORCID 0000-0001-9480-4621
José Correa-BasurtoLaboratorio de Modelado Molecular y Diseño de Fármacos de la Escuela Superior de Medicina, Instituto Politécnico Nacional, Gustavo A. Madero, Mexico City 07360, Mexico.ORCID 0000-0002-4973-5265
Martiniano BelloLaboratorio de Modelado Molecular y Diseño de Fármacos de la Escuela Superior de Medicina, Instituto Politécnico Nacional, Gustavo A. Madero, Mexico City 07360, Mexico.ORCID 0000-0002-9686-0755
Libia Vega-LoyoDepartamento de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-I.P.N.), Gustavo A. Madero, Mexico City 07360, Mexico.ORCID 0000-0002-4993-5267
María Del Rocío Thompson-BonillaLaboratorio de Medicina Genómica, Hospital Regional 1 de Octubre, ISSSTE, Gustavo A. Madero, Mexico City 07360, Mexico.
Rosaura Hernández-RivasDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-I.P.N.), Gustavo A. Madero, Mexico City 07360, Mexico.ORCID 0000-0002-5275-0730
Miguel VargasDepartamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (CINVESTAV-I.P.N.), Gustavo A. Madero, Mexico City 07360, Mexico.ORCID 0000-0002-3031-9798
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXInstituto Nacional de Investigaciones Nucleares · MXInstituto Politécnico Nacional · MXInstitute for Social Security and Services for State Workers · MX
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
In 40-50% of colorectal cancer (CRC) cases, K-Ras gene mutations occur, which induce the expression of the K-Ras4B oncogenic isoform. K-Ras4B is transported by phosphodiesterase-6δ (PDE6δ) to the plasma membrane, where the K-Ras4B-PDE6δ complex dissociates and K-Ras4B, coupled to the plasma membrane, activates signaling pathways that favor cancer aggressiveness. Thus, the inhibition of the K-Ras4B-PDE6δ dissociation using specific small molecules could be a new strategy for the treatment of patients with CRC. This research aimed to perform a preclinical proof-of-concept and a therapeutic potential evaluation of the synthetic I-C19 and
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.